Lilly again beats revenue estimates, raises full-year guidance

For the second consecutive quarter, Eli Lilly and Co. (NYSE:LLY) beat consensus revenue estimates and raised its full-year guidance. In its 2Q18 earnings released Tuesday, the pharma reported revenues of $6.4

Read the full 312 word article

User Sign In